Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Diagnosing Rickettsia: crimps, complications, and coups.

Asnis D, Hsiao B, Beekman K.

Clin Infect Dis. 2015 Feb 1;60(3):493-4. doi: 10.1093/cid/ciu846. Epub 2014 Oct 29. No abstract available.

PMID:
25355903
2.

Ohio statewide quality-improvement collaborative to reduce late-onset sepsis in preterm infants.

Kaplan HC, Lannon C, Walsh MC, Donovan EF; Ohio Perinatal Quality Collaborative.

Pediatrics. 2011 Mar;127(3):427-35. doi: 10.1542/peds.2010-2141. Epub 2011 Feb 21.

PMID:
21339274
3.

Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder.

Smith DC, Mackler NJ, Dunn RL, Hussain M, Wood D, Lee CT, Sanda M, Vaishampayan U, Petrylak DP, Quinn DI, Beekman K, Montie JE.

J Urol. 2008 Dec;180(6):2384-8; discussion 2388. doi: 10.1016/j.juro.2008.08.075. Epub 2008 Oct 18.

4.

Hormonal approaches in prostate cancer: application in the contemporary prostate cancer patient.

Beekman KW, Hussain M.

Urol Oncol. 2008 Jul-Aug;26(4):415-9. doi: 10.1016/j.urolonc.2007.11.003. Review.

PMID:
18593620
5.

A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer.

Lee RT, Beekman KE, Hussain M, Davis NB, Clark JI, Thomas SP, Nichols KF, Stadler WM.

Clin Genitourin Cancer. 2008 Mar;6(1):21-4. doi: 10.3816/CGC.2008.n.003.

6.

New molecular targets and novel agents in the treatment of advanced urothelial cancer.

Beekman KW, Bradley D, Hussain M.

Semin Oncol. 2007 Apr;34(2):154-64. Review.

PMID:
17382799
7.

Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.

Beekman KW, Colevas AD, Cooney K, Dipaola R, Dunn RL, Gross M, Keller ET, Pienta KJ, Ryan CJ, Smith D, Hussain M.

Clin Genitourin Cancer. 2006 Mar;4(4):299-302.

PMID:
16729916
8.

Targeted approaches for the management of metastatic prostate cancer.

Beekman KW, Hussain M.

Curr Oncol Rep. 2006 May;8(3):206-12. Review.

PMID:
16618385
9.

Second-line chemotherapy for prostate cancer: patient characteristics and survival.

Beekman KW, Fleming MT, Scher HI, Slovin SF, Ishill NM, Heller G, Kelly WK.

Clin Prostate Cancer. 2005 Sep;4(2):86-90.

PMID:
16197608
10.

Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen.

Beekman K, Morris M, Slovin S, Heller G, Wilton A, Bianco F Jr, Scardino PT, Scher HI.

Urology. 2005 May;65(5):947-52.

PMID:
15882729
11.

Gait characteristics in multiple sclerosis: progressive changes and effects of exercise on parameters.

Gehlsen G, Beekman K, Assmann N, Winant D, Seidle M, Carter A.

Arch Phys Med Rehabil. 1986 Aug;67(8):536-9.

PMID:
3741079

Supplemental Content

Loading ...
Support Center